The 8th annual World Orphan Drug Congress was held in Barcelona on 13-15th of November 2017. SOM Biotech's CEO, Dr. Raúl Insa, did a “Pitch & Partner” session on Drug Repurposing in CNS Orphan Indications. The World Orphan Drug Congress is the marketplace for orphan drug professionals looking at the complete value chain of orphan drug…
World Orphan Drug Congress Europe 2017
posted on November 9, 2017
SOM Biotech at Bio-Europe 2017
posted on October 31, 2017
Dr. Raúl Insa (CEO) and Raj Airey (Chief Strategy Officer) had the opportunity to discuss SOM’s current programs at Europe´s largest life science partnering conference Bio-Europe 2017, that was held in Berlin November 6-9, 2017. BIO-Europe’s world-class workshops, panels and active exhibition along with thousands of pre-scheduled one-to-one meetings make this event an unrivaled forum…
SOM Biotech at International Symposium on “Rare diseases and Big Data”
posted on October 24, 2017
Dr. Ferruccio Palazzesi, SOM Biotech Senior Computational Chemist, attended the International Symposium on “Rare diseases and big data, from research to clinical practice”, organized by Bioinformatics Barcelona Association (BIB) and Fundación Ramon Areces. Event took place in Barcelona 26-27th October 2017. The symposium covered clinical management of rare diseases, as well as current research and…
SOM Biotech releases a new version of its proprietary drug repurposing process
posted on October 19, 2017
Using the latest modular workflow technologies, SOM Biotech has released a new version of his proprietary drug repurposing virtual process. This update has had the goal to improve more than 30% the performance, scalability and velocity of the process. This software update highlights the SOM Biotech strong commitment to grow day-by-day, in order to continue…
Nippon Chemiphar and SOM Biotech to Cooperate on New, Orphan Disease Indications for bevantolol (Calvan®)
posted on October 14, 2017
SOM Biotech has determined and validated an entirely new usage for Nippon Chemiphar’s marketed hypertension therapy bevantolol (Calvan®). SOM, after using a proprietary ligand analysis computational algorithm and completing the preclinical assays, determined that bevantolol (coded SOM3355 by SOM) is a highly effective Vesicular Monoamine Transporter Type 2 (VMAT2) inhibitor, a class of compounds that…
SOM Biotech at 2017 ASEBIO Investor Day
posted on September 26, 2017
SOM Biotech was one of the presenting companies at 2017 ASEBIO Investor Day. ASEBIO Investor Day is an event which allows Spanish innovative biotechnology projects to be introduced to an audience of leading investors and pharmaceutical companies. The event is organized by ASEBIO, the Spanish Bioindustry Association, with the support of ICEX - the Spanish Foreign Trade…